Studies have shown that PCSK9 performs as a ligand that moves into the cell by binding to the LDLR to form a receptor-ligand complex (Seidah & Prat, 2022), so it seems plausible that PCSK9 is highly expressed in tumor tissue and low in the serum of PC patients. This evidence concerns the gene LDLR and pachyonychia congenita.